IPO Year: 2021
Exchange: NASDAQ
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/14/2023 | $9.00 | Overweight | Stephens |
7/19/2023 | Mkt Perform | Raymond James | |
2/15/2022 | $27.00 → $18.00 | Equal-Weight | Morgan Stanley |
1/6/2022 | $20.00 | Overweight | Piper Sandler |
10/15/2021 | Outperform | Cowen | |
8/17/2021 | Outperform | Cowen | |
8/17/2021 | Equal-Weight | Morgan Stanley | |
8/17/2021 | $26.00 | Equal-Weight | Morgan Stanley |
8/17/2021 | $28.00 | Buy | Goldman Sachs |
8/17/2021 | $28.00 | Overweight | Piper Sandler |
8-K - Cytek Biosciences, Inc. (0001831915) (Filer)
10-Q - Cytek Biosciences, Inc. (0001831915) (Filer)
8-K - Cytek Biosciences, Inc. (0001831915) (Filer)
8-K - Cytek Biosciences, Inc. (0001831915) (Filer)
SD - Cytek Biosciences, Inc. (0001831915) (Filer)
10-Q - Cytek Biosciences, Inc. (0001831915) (Filer)
8-K - Cytek Biosciences, Inc. (0001831915) (Filer)
ARS - Cytek Biosciences, Inc. (0001831915) (Filer)
DEFA14A - Cytek Biosciences, Inc. (0001831915) (Filer)
DEF 14A - Cytek Biosciences, Inc. (0001831915) (Filer)
FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure. During his tenure, Williams played key roles in the company's growth, spearheading initiatives that improved operational processes and paving the way for Cytek's future success. His leadership has been integral to enhancing the company's ef
FREMONT, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (NASDAQ:CTKB) announced that its San Diego reagent manufacturing facility has been awarded EN ISO 13485:2016 Quality Management System (QMS) certification. This certification encompasses the design, development, manufacturing, and distribution of reagents and accessories, highlighting the company's adherence to rigorous quality standards. Cytek's manufacturing facilities in Wuxi, China and its headquarters in Fremont, California are also EN ISO 13485:2016 certified. ISO 13485 is a globally recognized standard that outlines the requirements for a comprehensive QMS specific to the medical device industry. It is
FREMONT, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences. UBS Genomic Medicine Summit in Dana Point, CAPanel discussion: Expanding Horizons - Spatial and Beyond on Wednesday, August 14, 2024, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time Wells Fargo Healthcare Conference in Boston, MAParticipating in investor 1x1 meetings on Wednesday and Thursday, September 4-5, 2024 Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NYFireside chat on September 6, 2024, at 4:45 a.m. Pacific Time / 7:45 a.m. East
FREMONT, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Total revenue for the second quarter of 2024 was $46.6 million, representing a 4% increase sequentially over the first quarter of 2024 and a 6% decrease over the second quarter of 2023For the first half of 2024, total revenue grew 5% compared to the first half of 2023Launched Enhanced Small Particle (ESP™) detection, an upgrade option for the Cytek Aurora™ and Northern Lights™ systems for the analysis of viruses and other sub-
FREMONT, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (NASDAQ:CTKB) announced that it has developed a revolutionary tool to automate panel design. The company has expanded the capabilities of the Panel Builder tool within its Cytek® Cloud digital ecosystem with the addition of SpectroPanel™ tool, a proprietary new intelligent algorithm which suggests optimized panels in minutes. Optimized for Cytek's Full Spectrum Profiling™ (FSP™) technology, the SpectroPanel tool automates the assignment of fluorochromes to markers, removing the labor-intensive manual process. This allows scientists to jumpstart their panel design process. With over 11,000 users and count
FREMONT, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced it will report financial results for the second quarter 2024 after market close on Tuesday, August 6, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com. About Cytek Biosciences, Inc. Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the
FREMONT, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved the repurchase of up to an aggregate of $50 million of its common stock, subject to compliance with applicable law. The Company's common stock is listed on The Nasdaq Global Select Market under the symbol "CTKB". The repurchase program will continue until December 31, 2024 unless extended or shortened by the Board of Directors. Any repurchases would be made in the open market and/or in privately negotiated transactions, and may be made from time to time or in one or more larger repurchases. The program
FREMONT, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, FL. Cytek management is scheduled to participate in a fireside chat on Wednesday, June 12th at 9:20 a.m. Eastern Time / 6:20 a.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: investors.cytekbio.com. About Cytek Biosciences, Inc. Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next
FREMONT, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (NASDAQ:CTKB) announced that its 1-laser and 2-laser 6-color TBNK reagent cocktails have received China National Medical Products Administration (NMPA) approval for clinical diagnostic use on the Cytek® Northern Lights™-Clinical (NL-CLC™) cell analysis systems in hospitals, laboratories and clinics across China. This is the first clinical 1-laser based 6-color TBNK assay supported by Full Spectrum Profiling™ (FSP™) capability. Clinical TBNK analysis is routinely used to assess and monitor immune system status for various medical conditions, with TBNK reagents enabling the identification and quantification
FREMONT, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, officially announced its Enhanced Small Particle (ESP™) Detection Option for its flagship Cytek Aurora™ and Cytek Northern Lights™ cell analysis systems. With this optional upgrade, these systems show superior sensitivity and resolution of subcellular materials, including extracellular vesicles (EVs), while maintaining high resolution and high parameter capabilities for cell analysis, making them the preferred choice among researchers and clinicians. Exosomes are the most commonly studied EV, with a market estimated to increase from $227.5 million in 20
SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)
SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)
SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)
SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)
SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)
SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)
SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)
SC 13D/A - Cytek Biosciences, Inc. (0001831915) (Subject)
SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)
SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)
FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure. During his tenure, Williams played key roles in the company's growth, spearheading initiatives that improved operational processes and paving the way for Cytek's future success. His leadership has been integral to enhancing the company's ef
Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outlook FREMONT, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB) today announced that William (Bill) McCombe has been appointed chief financial officer of the company effective immediately. McCombe brings experience as a public company CFO at both large scale, and smaller, high growth technology companies. He was CFO at Velo3D, a leader in metal 3D printing systems for the aerospace and other industries, CFO at HZO, a leader in delivering protective nano coatings for electronics, and EVP and CFO at Maxar Technologies, a multi-billion-
FREMONT, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the appointment of Philippe Busque, Ph.D. as Senior Vice President of Global Sales & Services. In this newly created position, Dr. Busque will lead an enhanced global sales organization encompassing all customer facing functions worldwide, including sales, service, and technical application support, building on the recently integrated sales team that combines the original Cytek sales force with the Amnis® and Guava® sales force. "Philippe's extensive global sales and marketing experience as an executive at several life science companies, incl
FREMONT, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the appointment of Todd Garland as Chief Commercial Officer, Cytek Biosciences, Inc. Garland's appointment is effective immediately, reporting directly to Dr. Wenbin Jiang, Chairman and CEO of Cytek Biosciences. "I have long admired Cytek's advanced technology and products, and I am particularly pleased to join the company because I believe Cytek has a real opportunity to become the premier company in the cell analysis industry," commented Garland. Garland's prior professional career spans BD Biosciences, CareFusion and Cardinal
4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
3 - Cytek Biosciences, Inc. (0001831915) (Issuer)
4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
Stephens initiated coverage of Cytek Biosciences with a rating of Overweight and set a new price target of $9.00
Raymond James initiated coverage of Cytek Biosciences with a rating of Mkt Perform
Morgan Stanley reiterated coverage of Cytek Biosciences with a rating of Equal-Weight and set a new price target of $18.00 from $27.00 previously
Piper Sandler resumed coverage of Cytek Biosciences with a rating of Overweight and set a new price target of $20.00
Cowen resumed coverage of Cytek Biosciences with a rating of Outperform
Cowen initiated coverage of Cytek Biosciences with a rating of Outperform
Morgan Stanley initiated coverage of Cytek Biosciences with a rating of Equal-Weight
Morgan Stanley initiated coverage of Cytek Biosciences with a rating of Equal-Weight and set a new price target of $26.00
Goldman Sachs initiated coverage of Cytek Biosciences with a rating of Buy and set a new price target of $28.00
Piper Sandler initiated coverage of Cytek Biosciences with a rating of Overweight and set a new price target of $28.00
FREMONT, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Total revenue for the second quarter of 2024 was $46.6 million, representing a 4% increase sequentially over the first quarter of 2024 and a 6% decrease over the second quarter of 2023For the first half of 2024, total revenue grew 5% compared to the first half of 2023Launched Enhanced Small Particle (ESP™) detection, an upgrade option for the Cytek Aurora™ and Northern Lights™ systems for the analysis of viruses and other sub-
FREMONT, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced it will report financial results for the second quarter 2024 after market close on Tuesday, August 6, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com. About Cytek Biosciences, Inc. Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the
FREMONT, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Total revenue was $44.9 million, representing a 21% increase over the corresponding period of 2023 Organic revenue was $37.3 million, representing an increase of 11% compared to the first quarter of 2023First quarter revenue from the product lines acquired from Luminex Corporation ("Luminex") on February 28, 2023 was $7.6 million Opened a new 50,000-square-foot facility in Wuxi, China to meet growing global demand for cutting-edge
FREMONT, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced it will report financial results for the first quarter 2024 after market close on Wednesday, May 8th, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com. About Cytek Biosciences, Inc. Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advanci
FREMONT, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2023. Recent Highlights Total revenue was $58.6 million, or $58.2 million on a non-GAAP constant currency basis, for the fourth quarter of 2023, representing 21% and 14% increases, respectively, over the corresponding period of 2022 Organic revenue was $48.8 million, representing an increase of 1% compared to the fourth quarter of 2022. Fourth quarter revenue from the product lines acquired from Luminex Corporation ("Luminex") on February
FREMONT, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 28th, 2024. The company's management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com. About Cytek Biosciences, Inc. Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company
FREMONT, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights Total revenue was $48.0 million, representing 19% growth over the third quarter of 2022 Total revenue on a non-GAAP constant currency basis was $47.7 millionOrganic revenue was $41.2 million, representing an increase of 2% compared to the third quarter of 2022. Third quarter revenue from the product lines acquired from Luminex Corporation on February 28, 2023, was $6.8 million Achieved ISO 13485 Quality Management System certi
FREMONT, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced it will report financial results for the third quarter 2023 after market close on Tuesday, November 7th, 2023. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com. About Cytek Biosciences Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next gene
FREMONT, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB) today reported financial results for the second quarter ended June 30, 2023. Recent Highlights Total revenue was $49.7 million, representing 24% growth over the second quarter of 2022 Total revenue on a non-GAAP constant currency basis was $50.0 millionOrganic revenue for Cytek's existing product portfolio was $41.5 million in the second quarter of 2023, representing an increase of 3% compared to the second quarter of 2022. Second quarter revenue from the product lines acquired from the Luminex Corporation transaction, which closed February 28, 2023, was $8.2 million
FREMONT, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced it will report financial results for the second quarter 2023 after market close on Tuesday, August 8th, 2023. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com. About Cytek BiosciencesCytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next generat
Piper Sandler analyst David Westenberg maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price target from $10 to $8.5.
Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. The company reported quarterly sales of $44.900 million which beat the analyst consensus estimate of $43.586 million by 3.01 percent. This is a 21.06 percent increase over sales of $37.088 million the same period last year.
Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outlookFREMONT, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB) today announced that William (Bill) McCombe has been appointed chief financial officer of the company effective immediately. McCombe brings experience as a public company CFO at both large scale, and smaller, high growth technology companies. He was CFO at Velo3D, a leader in metal 3D printing systems for the aerospace and other industries, CFO at HZO, a leader in delivering protective nano coatings for electronics, and EVP and CFO at Maxar Technologies, a multi-billion-dolla
Piper Sandler analyst David Westenberg maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price target from $11 to $10.
U.S. stocks were lower, with the Dow Jones index falling around 80 points on Monday. Shares of Tesla, Inc. (NASDAQ:TSLA) fell during Monday’s session after the company reportedly saw a decline in February China sales. Tesla sold 60,365 electric vehicles made in China in February, according to preliminary data released by the China Passenger Car Association, as reported by CnEVPost. The breakdown between exports and domestic sales will be available when the detailed report is released in a week. Tesla shares fell 5.4% to $191.79 on Monday. Here are some other big stocks recording losses in today’s session. MMTec, Inc. (NASDAQ:MTC) shares fell 21.8% to $2.00. Avidity Biosciences, Inc
- SEC Filing
Shares of Butterfly Network, Inc. (NASDAQ:BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. Butterfly Network posted GAAP loss of 21 cents per share versus market estimates for a loss of 14 cents per share. The company’s quarterly sales came in at sales came in $16.52 million versus estimates of $15.35 million. Butterfly Network shares dipped 21.7% to $1.1588 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Enveric Biosciences, Inc. (NASDAQ:ENVB) gained 177.1% to $2.30 after the company announced it has signed three non-binding term sheets with an undisclosed biotechnology company to purs